PROK - NASDAQ

ProKidney Corp.

PROK·NASDAQ

$1.73

-8.9%

HealthcareBiotechnology

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$581.72M

EPS-0.5200

P/E Ratio-3.33

Earnings Date08/06/2026

-54.13%

Return on Invested Capital

20%

3Y+80.0%

5Y-77.0%

10Y-52.0%

6.82%

Return on Equity

11%

3Y-31.0%

5Y-103.0%

10Y-101.0%

-20.56%

Return on Assets

48%

3Y-1.0%

5Y-87.0%

10Y-95.0%

ProKidney Corp. Management Team

PROK · NASDAQ

Mr. Nikhil L. Pereira-Kamath

Chief Business Officer

male

Dr. Bruce Culleton M.D.

Chief Executive Officer & Director

Compensation

$1,015,802

Born 1969(Age 57)

Mr. James Coulston CPA

Chief Financial Officer

Compensation

$533,152

Born 1977(Age 49)

male

Mr. Richard Williams

Chief Information Officer

male

Mr. Todd C. Girolamo Esq., J.D., M.B.A.

Chief Legal Officer & Secretary

Compensation

$635,858

Born 1965(Age 61)

male

Ms. Carla Poulson

Chief People Officer

female

Dr. Darin J. Weber Ph.D.

Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access

Born 1968(Age 58)

Dr. Ulrich Ernst Ph.D.

EVice President of Science and Technology

Compensation

$622,743

Born 1963(Age 63)

Dr. Joseph M. Stavas M.D., M.P.H.

SVice President of Clinical Affairs

Ms. Anu Biswas

Senior Vice President of Manufacturing & Operations

female

INSIDER TRANSACTIONS

ProKidney Corp. Insider Positioning

PROK · NASDAQ

During the last 12 months, insiders have sold $932K worth of PROK shares, with no buying activity reported.

3 Months

Bought

0.00

Sold

0.00

Net Activity

+$0

3-6 Months

Bought

0.00

Sold

0.00

Net Activity

+$0

6-9 Months

Bought

0.00

Sold

227.4K

619.36K

Net Activity

-619K

-$619K

9-12 Months

Bought

0.00

Sold

103.5K

312.51K

Net Activity

-313K

-$313K

Top Buyers

No buying activity

Top Sellers

PBJ

Pereira Brian Jg

Director

227.4K shares•1 transactions

$619K

WDJ

Weber Darin J.

Officer: Chief Regulatory Officer

103.5K shares•1 transactions

$313K

Insider Activity Analysis

Net Insider Sentiment

Bearish

Strong bearish signal with $932K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.

Buy/Sell Ratio

0.00:1

Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.

Insider Participation

High Selling

2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.

SEC PROXY FILINGS

SEC Filings

PROK - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
DEF 14A DEF 14A 2026 N/A	April 17, 2026	May 28, 2026	2026	View Filing
DEF 14A DEF 14A 2024 N/A	April 26, 2024	May 30, 2024	2024	View Filing
DEF 14A DEF 14A 2023 N/A	May 26, 2023	June 29, 2023	2023	View Filing

Showing 1 to 3 of 3 filings

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.